Advertisement
 
YOU ARE HERE: LAT HomeCollectionsAmyloid
IN THE NEWS

Amyloid

NEWS
April 8, 2002 | From Times Wire Reports
A single dose of an antibody that cleans up brain-clogging proteins improves memory in mice and might lead to an Alzheimer's disease vaccine for people, researchers reported. A team at Lilly Research Laboratories in Indianapolis, owned by Eli Lilly; Washington University in St. Louis; and Universite Louis Pasteur in Strasbourg, France, has been reporting steady progress in mice with an antibody called m266.
Advertisement
CALIFORNIA | LOCAL
December 21, 2000 | From Times staff and wire reports
A potential Alzheimer's vaccine prevented a decline in learning and memory in mice, according to two new studies in today's Nature. The reports suggest a possibility that a vaccine can be developed to treat dementia and the loss of learning ability and memory associated with the disease in people. Tests involving humans could begin within a year.
CALIFORNIA | LOCAL
April 13, 2000
Researchers at the Oklahoma Medical Research Foundation say they have identified a highly effective inhibitor of the enzyme that plays a key role in the onset of Alzheimer's disease. Memapsin 2, also known as beta-secretase, cleaves a protein called amyloid precursor protein, producing protein fragments that damage brain cells. The team reported in Wednesday's Journal of the American Chemical Society that the new inhibitor blocks this process in the test tube. It has not been tested in humans.
NEWS
April 15, 1991 | THOMAS H. MAUGH II, TIMES SCIENCE WRITER
An important clue to the cause of memory loss associated with Alzheimer's disease has been discovered by researchers at City of Hope in Duarte. Biochemist Eugene Roberts and his City of Hope colleagues report today in the prestigious Proceedings of the National Academy of Sciences that injections of fragments of a brain protein called beta-amyloid into the brains of mice cause the animals to forget tasks they have just learned.
HEALTH
September 20, 2010 | By Jill U Adams, Special to the Los Angeles Times
Alzheimer's disease is a scourge of old age, robbing people of their ability to hold a thought or manage simple tasks of daily life. Once the disease takes hold, it doesn't let up, progressively worsening until death. Modern medicine has yet to discover a cure. Scientists don't even know what causes Alzheimer's and are only beginning to tease out the main risk factors for developing the disease, besides age itself. One of the leading candidates is Type 2 diabetes, in which patients stop responding properly to insulin and can't convert glucose into energy.
CALIFORNIA | LOCAL
December 9, 1991 | From Times Staff and Wire Reports
British scientists said last week that they had discovered a causal link between severe head injuries and Alzheimer's disease, a terminal brain disorder that afflicts an estimated 4 million elderly people in the United States. "It has been argued for a long time that Alzheimer's has several different causes. Our data is the first direct evidence that head injury may be one significant causative factor," said Dr. Gareth Roberts of London's St. Mary's Hospital Medical School.
HEALTH
January 22, 2007 | From Times wire reports
Scientists have identified a gene that increases the risk for late-onset Alzheimer's and provides another clue into the complex mind-robbing disease. The gene -- SORL1 -- stands out because it's been tested in four ethnic groups and a form of it seems to confer a risk in all of them -- including North Europeans, Caribbean Latinos, African Americans and Israeli Arabs.
CALIFORNIA | LOCAL
July 8, 1999
Vaccination with a protein that plays a key role in Alzheimer's disease can halt progression of an Alzheimer's-like disorder in mice and may even reverse some of the symptoms, according to a report in today's Nature. The protein, called AN-1792, is a modified form of beta-amyloid peptide, one of the proteins found in the plaques and tangles in the brain characteristic of Alzheimer's disease.
NEWS
December 3, 2010 | By Shari Roan, Los Angeles Times
Disease-modifying treatments for Alzheimer's disease have proved elusive. However, a study in mice published this week suggests that a treatment strategy relying on gene therapy may be worth pursuing. Researchers at the Gladstone Institute of Neurological Disease in San Francisco found that mice and humans with Alzheimer's disease have unusually low levels of an enzyme called EphB2 in the parts of the brain that control memory. EphB2 plays an important role in fostering communication between brain cells.
NEWS
October 22, 1999 | PAUL JACOBS, TIMES STAFF WRITER
Scientists at Amgen have isolated an elusive brain chemical believed to play a crucial role in the development of Alzheimer's disease. Reporting their findings in today's edition of Science, the researchers hope the discovery will lead to targeted treatments that can halt the advance of this mind-devouring disease that afflicts an estimated 4 million Americans.
Los Angeles Times Articles
|